SequelSEC

Ocean Biomedical, Inc. OCEA

Pharmaceutical Preparations · CIK 0001869974 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2024-12-31
Operating income
-$3.80M
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

Ocean Biomedical, Inc. (OCEA) reported net income of -$9.48M for the fiscal year ended 2024-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Ocean Biomedical, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Ocean Biomedical, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$3.80M-$10.21M-$16.12M
Net income-$9.48M-$114.47M-$17.36M
Research & development$26.00K$709.00K$8.41M
Weighted-average diluted sharesshares 27.50Mshares 26.29Mshares 23.36M
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPS$-0.34$-4.35$-0.74
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$3.77M$9.50M$7.71M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Ocean Biomedical, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-31
Cash & equivalentsUnavailableUnavailableUnavailable
Total assets$902.00K$5.50M$1.84M
Current assets$812.00K$2.11M$1.84M
Total liabilities$98.52M$96.26M$12.66M
Current liabilities$33.89M$30.01M$12.66M
Total equity incl. NCI-$97.62M-$90.76M-$10.82M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$15.90M$16.18M$11.44M

Cash flow

Ocean Biomedical, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-31
Operating cash flow-$4.18M-$9.43M-$993.00K
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailable-$2.10M
Financing cash flow$3.40M$10.40M$967.00K
Net change in cash-$780.00K$970.00K-$26.00K
Stock-based compensationUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Ocean Biomedical, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio0.02x0.07x0.15x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OCEA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-05-15View SEC filing
10-K · Filed 2025-04-08View SEC filing
10-Q · Filed 2025-01-13View SEC filing
10-Q · Filed 2024-12-23View SEC filing
10-Q · Filed 2024-12-23View SEC filing
10-K · Filed 2024-11-25View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

cash flow reconciliationreview2022-12-31

Operating, investing and financing flows differ from the reported change in cash by 2100000, beyond tolerance 1000000.